Geron Corporation (GERN)

Nasdaq: GERN · Pharmaceutical Preparations · Foster City, CA · filing with the SEC since 1996

Full chart Alerts Compare

Grade3.5

◀ Past 4.3● Present 3.5▶ Future 3.1

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2023, as filed

Revenue$237,000-60.2%

Net income-$184M-29.8%

Earnings per share$-0.32+13.5%

Operating cash flow-$168M-31.7%

Cash$70.0M+23.2%

Debt$35.1M+16.0%

Shareholders’ equity$248M+209.9%

Shares, diluted570.6M+49.9%

Return on equity-37.0%

The recordfrom its filings

Filings in 202642

Newest filingNov 10 · SCHEDULE 13G

Annual reportMar 2, 2026

Quarterly reportNov 4, 2026

Next report due10-K by Mar 1

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted206

Filer categoryLarge accelerated filer

Trailing twelve months to Sep 2026Net income -$47.8MCash from operations -$90.5Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Oct 28, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 1, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 7, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Aug 6, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 5, 2026 · SEC EDGAR · Form S-8

Employee stock plan registration

Open the filing on sec.gov

Aug 5, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Geron Corporation is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Foster City, CA.

Newest on the record

Large holder notice on Nov 10. Before it, current report on Nov 4.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 1, 2027.

About GERN

Geron Corporation is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Foster City, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported a loss of $84 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersFoster City, CA

Business modelPre-revenue company

ExchangeNasdaq

Filing since1996

Fiscal year endsDec 31

SEC number (CIK)886744

Peers on fileEWTX, OLMA, DNTH, CNTN

Who runs it

Financial performance

In fiscal 2023 Geron’s revenue was $237,000, down 60.2% from $596,000 the year before. It made a net loss of $184.1 million.

Annual report, filed Mar 2, 2026.

Financial statements

The grade

Geron grades 3.5 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past4.3

● Present3.5

▶ Future3.1

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton GERN · research, not advice